Pneumology - Reviews Open access

Clinical and biomarker significance of interleukin-4 and interleukin-13 in acute exacerbations and the frequent exacerbator phenotype of chronic obstructive pulmonary disease: a systematic review

Authors

Published
17 November 2026
Issue
Early Access
Section
Pneumology - Reviews

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are one of the major causes of morbidity, mortality, and hospitalization; reliable inflammatory biomarkers predicting exacerbation risk and guiding emerging interleukin (IL)-targeted therapies are still undefined. IL-4 and IL-13 are key T-helper 2 cytokines implicated in eosinophilic airway inflammation and remodeling, but their clinical and prognostic relevance in COPD is still controversial.

MEDLINE and EMBASE databases were manually searched from inception to December 2025, including observational studies reporting quantitative IL-4 and/or IL-13 levels in adults with COPD and healthy controls, with measurements in serum by enzyme-linked immunosorbent assay or V-PLEX immunoassay. Study selection, data extraction, and quality assessment (Newcastle-Ottawa Scale) were performed independently by three reviewers, following PRISMA recommendations.

Of 1147 records screened, 5 cohort studies (total patient number: 1168) met inclusion criteria. Across studies, serum IL-4 was consistently higher in AECOPD than in healthy controls, with IL-13 also frequently elevated during exacerbations. Comparisons between AECOPD and stable COPD yielded non-significant results. Two studies reported higher serum IL-4 in frequent versus infrequent exacerbators, whereas IL-13 was not as significantly high as IL-4. In stable COPD, IL-4 and IL-13 showed only modest, often non-significant increases versus controls. Available evidence suggests that IL-4 and IL-13 are variably upregulated in COPD, with more pronounced elevations during AECOPD and a possible association between higher IL-4 and frequent exacerbations. However, small sample sizes, methodological heterogeneity, and limited longitudinal data can’t lead to definitive conclusions, requiring the need for larger, well-designed studies to validate IL-4/IL-13 as prognostic biomarkers and therapeutic targets in COPD.

References

  1. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease: 2025 Report. Available from: https://goldcopd.org/2025-gold-report/.
  2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442. DOI: https://doi.org/10.1371/journal.pmed.0030442
  3. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-71. DOI: https://doi.org/10.1164/rccm.201104-0597OC
  4. López-Campos JL, Arellano E, Calero C, et al. Determination of inflammatory biomarkers in patients with COPD: a comparison of different assays. BMC Med Res Methodol 2012;12:40. DOI: https://doi.org/10.1186/1471-2288-12-40
  5. Edalatifard M, Mortaz E, Ghorbani F, et al. Inflammatory serum biomarker pattern in emphysema and chronic bronchitis phenotypes of acute exacerbation of chronic obstructive pulmonary disease. Tanaffos 2023;22:317-24.
  6. Miotto D, Ruggieri MP, Boschetto P, et al. Interleukin-13 and -4 expression in the central airways of smokers with chronic bronchitis. Eur Respir J 2003;22:602-8. DOI: https://doi.org/10.1183/09031936.03.00046402
  7. Matsunaga K, Koarai A, Koto H, et al. Guidance for type 2 inflammatory biomarkers. Respir Investig 2025;63:273-88. DOI: https://doi.org/10.1016/j.resinv.2025.01.003
  8. Bal SM, Bernink JH, Nagasawa M, et al. IL-1β, IL-4 and IL-12 control the fate of group 2 innate lymphoid cells in human airway inflammation in the lungs. Nat Immunol 2016;17:636-45. DOI: https://doi.org/10.1038/ni.3444
  9. Bhatt SP, Rabe K, Hanania N, et al. Efficacy and safety of dupilumab in COPD with type 2 inflammation guided by blood eosinophils: the BOREAS Study. N Engl J Med 2023;389:105-14. DOI: https://doi.org/10.1056/NEJMoa2303951
  10. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with blood eosinophil evidence of type 2 inflammation. N Engl J Med 2024;390:2274-83. DOI: https://doi.org/10.1056/NEJMoa2401304
  11. Qaseem A, Wilt TJ, Weinberger SE, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline update from the American College of Physicians, American College of Chest Physicians, American Thoracic Society, and European Respiratory Society. Ann Inter Med 2011;155:179-91. DOI: https://doi.org/10.7326/0003-4819-155-3-201108020-00008
  12. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Canada: Ottawa Hospital Research Institute.
  13. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. DOI: https://doi.org/10.1136/bmj.n71
  14. Lin Y, Sang L, Wang J, et al. Analysis of airway thickening and serum cytokines in COPD Patients with frequent exacerbations: a heart of the matter. Int J Chron Obstruct Pulmon Dis 2023;18:2353-64. DOI: https://doi.org/10.2147/COPD.S430650
  15. Sun J, Liu T, Yan Y, et al The role of Th1/Th2 cytokines played in regulation of specific CD4 + Th1 cell conversion and activation during inflammatory reaction of chronic obstructive pulmonary disease. Scand J Immunol 2018;88:e12674. DOI: https://doi.org/10.1111/sji.12674
  16. Zhao D, Abbasi A, Rossiter HB, et al Serum amyloid a in stable COPD Patients is associated with the frequent exacerbator phenotype. Int J Chron Obstruct Pulmon Dis 2020;15:2379-88. DOI: https://doi.org/10.2147/COPD.S266844
  17. Jiang M, Liu H, Li Z, et al. ILC2s induce adaptive Th2-type immunity in acute exacerbation of chronic obstructive pulmonary disease. Mediators Inflamm 2019;2019:3140183. DOI: https://doi.org/10.1155/2019/3140183
  18. Wei B, Sheng Li C. Changes in Th1/Th2-producing cytokines during acute exacerbation chronic obstructive pulmonary disease. J Int Med Res 2018;46:3890-902. DOI: https://doi.org/10.1177/0300060518781642
  19. Staples KJ, Ackland J, Lukose S, et al. Lung IL-13 gene signatures are associated with raised tissue eosinophils in COPD. Respir Res 2025;26:114. DOI: https://doi.org/10.1186/s12931-025-03177-x
  20. Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546-56. DOI: https://doi.org/10.1172/JCI36130
  21. Lee JS, Rosengart MR, Kondragunta V, et al. Inverse association of plasma IL-13 and inflammatory chemokines with lung function impairment in stable COPD: a cross-sectional cohort study. Respir Res 2007;8:64. DOI: https://doi.org/10.1186/1465-9921-8-64

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.